Skip to main content
. 2021 Oct 22;27(12):1561–1569. doi: 10.1111/cns.13742

FIGURE 4.

FIGURE 4

Comparison of platelet reactivities in different activating pathways at baseline and follow‐up visits. ADP, adenosine‐5’‐diphosphate (ADP); PAF, platelet aggregation factor; TXA2, thromboxane A2. Platelet reactivities in different pathways in trial groups at baseline and follow‐up, showing PAF was inhibited by Ginkgolide, while other traditional TAX2 and ADP levels were not associated with Ginkgolide treatment